Welcome to our dedicated page for Akero Therapeutics SEC filings (Ticker: AKRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing efruxifermin (EFX) for metabolic dysfunction-associated steatohepatitis (MASH) and related metabolic liver diseases. These regulatory documents offer detailed insight into Akero’s clinical programs, financial position, risk factors and corporate transactions.
Through its annual reports on Form 10-K and quarterly reports on Form 10-Q, Akero describes its business focus on serious metabolic diseases, outlines the design and objectives of the Phase 3 SYNCHRONY program, and discusses prior Phase 2b HARMONY and SYMMETRY results. Management’s discussion and analysis sections explain research and development spending, including costs associated with large global trials and manufacturing of clinical supplies for potential marketing applications.
Current reports on Form 8-K highlight material events. For example, Akero has filed an 8-K describing its Agreement and Plan of Merger with Novo Nordisk A/S and a wholly owned subsidiary of Novo Nordisk, under which Akero is expected to become a wholly owned subsidiary following stockholder approval and satisfaction of closing conditions. Another 8-K details the voluntary prepayment and termination of a prior loan agreement, providing context on changes in the company’s capital structure and debt obligations. Additional 8-K filings furnish quarterly earnings press releases and other significant updates.
Investors researching insider activity can review Forms 4 referenced in Akero’s proxy materials, which report changes in beneficial ownership by directors and executive officers. When available, proxy statements and related solicitation materials explain executive compensation, governance matters and, in connection with the proposed merger, information relevant to the stockholder vote. Stock Titan’s platform surfaces these filings as they are posted to EDGAR and adds AI-powered summaries to help readers interpret lengthy documents such as 10-Ks, 10-Qs, 8-Ks and proxy statements without having to parse every page manually.
Akero Therapeutics called a virtual special meeting for December 2, 2025 at 11:00 a.m. ET to ask stockholders to adopt its merger agreement with Novo Nordisk. If approved and completed, each Akero common share will be converted into the right to receive $54.00 in cash plus one contingent value right (CVR), subject to the CVR Agreement terms. The board unanimously recommends voting FOR the merger, an advisory executive compensation proposal, and a potential adjournment to solicit additional proxies.
Approval of the merger requires the affirmative vote of a majority of outstanding shares as of the November 7, 2025 record date. There were 82,324,445 shares outstanding; the majority threshold is 41,162,223 votes. As of November 6, 2025, Akero’s Nasdaq closing price was $53.91 per share.
Options in-the-money will be cashed out for the spread and one CVR per underlying share; RSUs vest and convert to cash at $54.00 per unit plus one CVR per unit. If the merger closes, Akero will become a wholly owned subsidiary of Novo and its stock will be delisted. If terminated under specified circumstances, Akero may owe a $165,000,000 termination fee, or be entitled to a $185,000,000 reverse termination fee from Novo.
Akero Therapeutics (AKRO) disclosed an insider transaction by its Chief Development Officer. On 11/04/2025, the officer exercised stock options and acquired 3,527 shares at $28.35 and 4,739 shares at $21.10 (code M). Following these transactions, the officer reported ownership of 74,800 shares, held directly.
A footnote states the reported amount was adjusted to correct a prior overstatement of common stock ownership. Another footnote confirms the options were vested and currently exercisable.
Akero Therapeutics called a virtual special meeting for stockholders to vote on adopting a Merger Agreement with Novo Nordisk, under which NN Invest Sub will merge into Akero and Akero will become a wholly owned subsidiary of Novo. If completed, each share of Akero common stock will be converted into the right to receive $54.00 in cash plus one contingent value right (CVR) tied to an Approval Milestone Payment under the CVR Agreement.
Akero’s board unanimously determined the transaction is advisable and fair and recommends voting FOR the Merger Proposal, the non-binding Compensation Proposal, and the Adjournment Proposal. Closing requires approval by a majority of outstanding shares. Appraisal rights are available for stockholders who comply with Delaware law procedures. Following closing, Akero’s shares will be delisted and deregistered.
Equity awards will be treated in cash at the Closing Consideration (plus a CVR per underlying share) as described, subject to exercise price mechanics. If the merger is not completed, Akero remains a standalone public company. The agreement includes a $165,000,000 termination fee payable by Akero in certain circumstances and a $185,000,000 reverse termination fee payable by Parent in specified cases.
Akero Therapeutics (AKRO) reported an insider transaction by its President and CEO, who is also a director. On 10/10/2025, the executive exercised 30,000 stock options at an exercise price of $19.87 per share and sold 30,000 shares of common stock at a $53.978 weighted-average price.
The transactions were effected under a Rule 10b5-1 trading plan dated August 16, 2024. Following the sale, the executive held 526,114 shares of common stock directly and 380,017 derivative securities (options) beneficially owned. The option grant vests in 48 equal monthly installments commencing on December 8, 2023.
Akero Therapeutics (AKRO) director Graham G. Walmsley reported multiple option exercises and acquisitions on
The transactions were disclosed on a single Form 4 filed by one reporting person; the filer disclaims beneficial ownership except for pecuniary interest. The signature block shows the form was signed by an attorney‑in‑fact on
Akero Therapeutics (AKRO) Form 4 shows Chief Scientific Officer Timothy Rolph used a Rule 10b5-1 plan to exercise 12,500 vested stock options at an exercise price of
Andrew Cheng, who serves as President and CEO and a director of Akero Therapeutics, Inc. (AKRO), reported a change in beneficial ownership dated 10/08/2025. The filing shows an acquisition of 52,212 shares/options at a price of $0.615 per share, and after the reported transaction Mr. Cheng beneficially owns 526,114 shares. The document also discloses a derivative entry for 52,212 stock options with the same exercise price; the filer notes these options are vested and currently exercisable. The Form is signed by an attorney-in-fact on 10/09/2025.
Akero Therapeutics agreed to be acquired by Novo Nordisk through a merger that will make Akero a wholly owned subsidiary of Novo Nordisk. The transaction includes cash consideration and a contingent value right (CVR) structure that awards one CVR per share and ties payments to specified regulatory and commercial milestones; in-the-money stock options will be cashed out plus converted into CVRs on a per-share basis. The merger is subject to customary closing conditions including antitrust and foreign investment clearances and approval by holders of a majority of Akero's common stock. Akero will file a proxy statement with additional details and warns that CVRs may yield no payment if milestones are not met and that regulatory approvals, competing offers, or other closing conditions could prevent or delay completion.
Deep Track entities and individual David Kroin reported ownership of 4,400,000 shares of Akero Therapeutics common stock, representing
The statement certifies the position was not acquired to change or influence control of the issuer and includes a joint filing agreement assigning responsibility for future amendments. The ownership percentage and shared control are material to investors because the stake exceeds the 5% reporting threshold and is publicly disclosed under SEC rules.
Akero Therapeutics, Inc. (AKRO) Form 144 shows an insider sale notice for 56,369 shares of common stock to be sold through J.P. Morgan Securities LLC on